Susan Halabi - Publications, H-index & Citations

Susan Halabi

duke university

81H指数

782论文数

3.2W被引数

收录论文 168

发表时间

Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success^☆癌症预防药物的随机III期临床试验：一项系统综述和试验成功的预测^☆

ESMO Open

IF8.3

2026-09-09

OAAI

A. Xu-Vuillard; B. Duso; B. Arun; J. Balmana; A. De Censi; N. Iyengar; N. Pashayan; C. Yu; D. Munoz-Espin; R. Fitzgerald; B. Ma; G. Kapetanakis; C. Turnbull; S. Halabi; S. Delaloge

AI-based augmentation of oncology clinical trials 基于人工智能的肿瘤学临床试验增强

Nature Reviews Clinical Oncology

IF82.2

2026-08-07

PREAI

Andrea Villa; Ashley L. Eadie; David Synnott; Rebecca Romanò; Max Piffoux; Evelyn Yi Ting Wong; Naomi Scheinerman; Daniel S. W. Tan; Filippo Guglielmo Maria de Braud; Miriam Koopman; Jarushka Naidoo; Madhusmita Behera; Selen Bozkurt; Susan Halabi; Rodrigo Dienstmann; Loic Verlingue; Arsela Prelaj; Ravi B. Parikh

Residual-based sieve maximum full likelihood estimation for the proportional hazards model 基于残差的筛子最大完全似然估计用于比例风险模型

COMMUNICATIONS IN STATISTICS-THEORY AND METHODS

IF0.8

2026-07-18

PREAI

Choi, Taehwa; Halabi, Susan; Kim, Hyotae; Wu, Yuan

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)雄激素受体剪接变体7的细胞质与核定位作为预测转移性去势抵抗性前列腺癌中雄激素受体通路抑制剂获益的指标（PROPHECY试验）

Prostate Cancer and Prostatic Diseases

IF5.8

2026-04-02

PREAI

Santosh Gupta; Siyuan Guo; Susan Halabi; Chenxi Yu; Hyotae Kim; Jane McKenzie; Daniel J. George; David M. Nanus; Russell Z. Szmulewicz; Daniel C. Danila; Jun Luo; Emmanuel S. Antonarakis; Andrew J. Armstrong

Comparing adaptive treatment strategies in two-stage randomized trials with grouped survival data 在分组生存数据的两阶段随机试验中比较适应性治疗策略

Lifetime Data Analysis

IF1

2026-04-02

PREAI

Sparkman, Monique; Halabi, Susan; Li, Zhiguo

A Two-Step Variable Selection Strategy for Multiply Imputed Survival Data Using Penalized Cox Models 使用惩罚性Cox模型的两步变量选择策略，用于多重插补生存数据

Bioengineering

IF3.7

2026-03-03

OAAI

Qian Yang; Bin Luo; Chenxi Yu; Susan Halabi

Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)风险分层与治疗获益：一项预测在探索多西他赛试验中转移性去势敏感型前列腺癌患者总生存期的模型（STOPCAP合作项目）

European Urology Focus

IF5.6

2026-02-18

PREAI

Susan Halabi; Bin Luo; Chenxi Yu; Larysa H.M. Rydzewska; Akash Roy; Hyotae Kim; Peter J. Godolphin; Laura Murphy; Michael A. Carducci; Gwenaëlle Gravis; Patrick Sfumato; Jean-Marie Boher; Nicholas D. James; Jayne F. Tierney; David Page; Christopher Sweeney; Siyuan Guo

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer 非转移性去势抵抗性前列腺癌的疾病进展模式及前列腺特异性抗原水平与进展风险的关联

Prostate Cancer and Prostatic Diseases

IF5.8

2026-02-12

OAAI

Alicia K. Morgans; Christopher J. D. Wallis; Susan Halabi; Andrew J. Armstrong; Patrick Adorjan; Mercedeh Ghadessi; Frank Verholen; Marc-Oliver Grimm

Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS 先前通过根治性前列腺切除术或放疗进行的局部治疗对达鲁柳胺治疗的ARAMIS患者的疗效和生活质量的影响

CANCER MEDICINE

IF3.1

2025-12-26

OAAI

Saar, Matthias; Fizazi, Karim; Shore, Neal D.; Smith, Matthew; Damber, Jan-erik; Semenov, Andrey; Ribal, Maria J.; Birtle, Alison; Rigaud, Jerome; Wallis, Christopher J. D.; Grimm, Marc-oliver; Halabi, Susan; Armstrong, Andrew J.; Mohamed, Ateesha F.; Adorjan, Patrick; Srinivasan, Shankar; Verholen, Frank; Morgans, Alicia K.; Siemens, D. Robert

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer 早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

Nature Communications

IF15.7

2025-12-17

OAAI

Soumyajit Roy; Yilun Sun; Maha Hussain; Kim N. Chi; Karim Fizazi; Ian D. Davis; Susan Halabi; Neeraj Agarwal; Simon Chowdhury; Bertrand Tombal; Scott C. Morgan; Shawn Malone; Pedro C. Barata; Michael Ong; Christopher J. D. Wallis; Alejandro Berlin; Umang Swami; Amar U. Kishan; Angela Y. Jia; Nicholas G. Zaorsky; Jorge A. Garcia; Prateek Mendiratta; Jason R. Brown; Vinod V. Subhash; Martin R. Stockler; Hayley Thomas; Rana R. McKay; Eric J. Small; Neal D. Shore; Fred Saad; Christopher J. Sweeney; Daniel E. Spratt

ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI)ESMO对基于AI的肿瘤学生物标志物的基本要求 (EBAI)

Annals of Oncology

IF65.4

2025-11-18

OAAI

M. Aldea; M. Salto-Tellez; A. Marra; R. Umeton; A. Stenzinger; M. Koopman; A. Prelaj; K.L. Kehl; S. Gilbert; M-E Leßmann; J. Lipkova; L. Provenzano; F. Meric-Bernstam; S. Halabi; J. Wu; A. Pellat; K.P.M. Suijkerbuijk; B. Besse; B. Ryll; C. Marchió

ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)ESMO关于大型语言模型在临床实践中应用的指南（ELCAP）

Annals of Oncology

IF65.4

2025-10-18

OAAI

E.Y.T. Wong; L. Verlingue; M. Aldea; M.A. Franzoi; R. Umeton; S. Halabi; N. Harbeck; A. Indini; A. Prelaj; E. Romano; E. Smyth; I.B. Tan; A. Valachis; J. Vibert; I.C. Wiest; Y.H. Yang; S. Gilbert; G. Kapetanakis; G. Pentheroudakis; M. Koopman; J.N. Kather

Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer 循环肿瘤DNA中的致病基因组改变可预测转移性去势抵抗性前列腺癌患者的总生存期

European Urology

IF25.2

2025-08-06

PREAI

Susan Halabi; Siyuan Guo; Bin Luo; Chenxi Yu; Todd P. Knutson; Anna Kobilka; Jacqueline Lyman; Himisha Beltran; Emmanuel S. Antonarakis; Matthew D. Galsky; Jonathan E. Rosenberg; Charles J. Ryan; Eric J. Small; W.Kevin Kelly; Michael J. Morris; David Page; Scott M. Dehm; Andrew J. Armstrong

Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer 放疗与手术为基础的治疗策略在高风险前列腺癌中的比较

European Urology Oncology

IF9.3

2025-07-19

PREAI

Soumyajit Roy; Yilun Sun; James A. Eastham; Martin Gleave; Christopher J.D. Wallis; Himisha A. Beltran; Amar U. Kishan; Angela Y. Jia; Nicholas G. Zaorsky; Himanshu Nagar; Jorge A. Garcia; Eric J. Small; Paul Nguyen; Gerhardt Attard; Rana R. McKay; Oliver Sartor; Alejandro Berlin; Seth A. Rosenthal; Susan Halabi; Randy Vince; Lee Ponsky; Scott C. Morgan; Raquibul Hannan; Adam Raben; Mack Roach; Jeff M. Michalski; Michael J. Morris; Howard M. Sandler; Daniel E. Spratt

How To Interpret Subgroup Analyses from Prospective Randomized Clinical Trials: What Clinicians Need To Know 如何解读前瞻性随机临床试验中的亚组分析：临床医师需要了解的内容

European Urology

IF25.2

2025-07-01

PREAI

Susan Halabi; Siyuan Guo

Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study 阿法替尼在具有神经营养因子1（NRG1）融合的实体瘤患者中的应用：Targeted Agent and Profiling Utilization Registry（TAPUR）研究中的病例系列

ESMO OPEN

IF8.3

2025-05-01

PREAI

Rodon, J.; Rothe, M.; Mangat, P. K.; Garrett-Mayer, E.; Cannon, T. L.; Hobbs, E.; Kalemkerian, G. P.; Hinshaw, D. C.; Gregory, A.; Grantham, G. N.; Halabi, S.; Schilsky, R. L.

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients

NATURE COMMUNICATIONS

IF15.7

2024-12-11

OAAI

Knutson, Todd P.; Luo, Bin; Kobilka, Anna; Lyman, Jacqueline; Guo, Siyuan; Munro, Sarah A.; Li, Yingming; Heer, Rakesh; Gaughan, Luke; Morris, Michael J.; Beltran, Himisha; Ryan, Charles J.; Antonarakis, Emmanuel S.; Armstrong, Andrew J.; Halabi, Susan; Dehm, Scott M.

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development ESMO肿瘤不可知分类器和筛选器 (etac-s): 一种评估分子引导疗法的肿瘤不可知潜力和指导药物开发的工具

ANNALS OF ONCOLOGY

IF65.4

2024-11-01

OAAI

Westphalen, C. B.; Martins-Branco, D.; Beal, J. R.; Cardone, C.; Coleman, N.; Schram, A. M.; Halabi, S.; Michiels, S.; Yap, C.; Andre, F.; Bibeau, F.; Curigliano, G.; Garralda, E.; Kummar, S.; Kurzrock, R.; Limaye, S.; Loges, S.; Marabelle, A.; Marchio, C.; Mateo, J.; Rodon, J.; Spanic, T.; Pentheroudakis, G.; Subbiah, V.

Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes 雄激素产生，摄取和转化 (APUC) 基因定义了具有不同临床结果的前列腺癌患者

JCI INSIGHT

IF6.1

2024-10-22

OAAI

Bergom, Hannah E.; Boytim, Ella; McSweeney, Sean; Sadeghipour, Negar; Elliott, Andrew; Passow, Rachel; Toye, Eamon; Li, Xiuxiu; Likasitwatanakul, Pornlada; Geynisman, Daniel M.; Dehm, Scott M.; Halabi, Susan; Sharifi, Nima; Antonarakis, Emmanuel S.; Ryan, Charles J.; Hwang, Justin

Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing 适应社会生态模型以解决黑人参与前列腺癌基因检测的差异

BMC PUBLIC HEALTH

IF3.6

2024-09-18

OAAI

Leader, Amy E.; Rebbeck, Timothy R.; Oh, William K.; Patel, Alpa V.; Winer, Eric P.; Bailey, LeeAnn O.; Gomella, Leonard G.; Lumpkins, Crystal Y.; Garraway, Isla P.; Aiello, Lisa B.; Baskin, Monica L.; Cheng, Heather H.; Cooney, Kathleen A.; Ganzak, Amanda; George, Daniel J.; Halabi, Susan; Hathaway, Feighanne; Healy, Claire; Kim, Joseph W.; Leapman, Michael S.; Loeb, Stacy; Maxwell, Kara N.; McNair, Christopher; Morgan, Todd M.; Prindeville, Breanne; Soule, Howard R.; Steward, Whitney L.; Suttiratana, Sakinah C.; Taplin, Mary-Ellen; Yamoah, Kosj; Fortune, Thierry; Bennett, Kris; Blanding-Godbolt, Joshua; Gross, Laura; Giri, Veda N.

研究方向